Darin J. Weber
About Darin J. Weber
Darin J. Weber at ProKidney
Darin J. Weber joined ProKidney in September 2020 as Senior Vice President of Regulatory Development. He was later promoted to Chief Regulatory Officer and Senior Vice President, where he leads the company's global regulatory strategy. His responsibilities include interfacing with regulatory authorities, overseeing quality management, and directing market access, pricing, and reimbursement efforts.
Darin J. Weber's Role in Regenerative Medicine
Darin J. Weber has over 25 years of experience in the fields of cellular and tissue-based regenerative medicine products. His career has been dedicated to advancing regulatory standards and strategies in this specialized medical sector. He has held several leadership roles, including at ProKidney, Medeor Therapeutics, and Mesoblast, where he has consistently focused on regulatory affairs and quality management in regenerative medicine.
Previous Positions Held by Darin J. Weber
Before joining ProKidney, Darin J. Weber served as Senior Vice President of Regulatory and Quality at Medeor Therapeutics from February 2016 to December 2019. Prior to that, he was the Executive Vice President of Global Regulatory Affairs and Quality Management at Mesoblast from June 2011 to February 2016. He also worked as a Senior Consultant for Cell and Gene Therapies at Biologics Consulting Group from February 2004 to May 2011. Early in his career, he held significant roles at the FDA, including Chief of Cellular Therapies Branch.
Educational Background of Darin J. Weber
Darin J. Weber received a B.S. in Molecular Biology from The Evergreen State College. He pursued further education to earn a Ph.D. in Biochemistry and Biophysics from Oregon State University. These academic qualifications have provided a foundation for his distinguished career in regulatory affairs and regenerative medicine.
Darin J. Weber's Contributions to Regulatory Standards
Darin J. Weber has been a long-serving member of United States Pharmacopeia (USP) expert committees for human tissues and advanced therapies. His work in these committees reflects his commitment to elevating regulatory standards and ensuring quality management in the field of regenerative medicine. His contributions are recognized for their impact on the development and implementation of regulatory frameworks in the U.S. and globally.